Literature DB >> 20001742

Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs.

Anuj Kumar Gupta1, Vishwa Mohan Katoch, Devendra Singh Chauhan, Rahul Sharma, Mradula Singh, Krishnamurthy Venkatesan, Vishnu Dutt Sharma.   

Abstract

Treatment of multidrug-resistant tuberculosis has become one of the major problems in public health. Understanding the molecular mechanisms of drug resistance has been central to tuberculosis research in recent times. DNA microarray technology provides the platform to study the genomic variations related to these mechanisms on a comprehensive level. To investigate the role of efflux pumps in drug resistance, we have constructed a custom DNA microarray containing 25 drug efflux pump genes of Mycobacterium tuberculosis (Indian Patent file no. 2071/DEL/2007) and monitored changes in the expression of these genes on exposure of common anti-tuberculous drugs. Expression profiling of efflux pump genes in multidrug-resistant M. tuberculosis isolates showed overexpression of 10 genes following exposure to various anti-tuberculous drugs. Although two of these genes (Rv3065 and Rv2938) have already been reported to be active drug efflux pumps in M. tuberculosis in earlier studies, the increased activities of other eight efflux pump genes (Rv1819, Rv2209, Rv2459, Rv2477c, Rv2688, Rv2846, Rv2994, and Rv3728) have been demonstrated in multidrug-resistant isolates by us for the first time. After confirmation of differential expressions of these genes by real-time reverse transcription polymerase chain reaction, it was observed that a simultaneous overexpression of efflux pump genes Rv2459, Rv3728, and Rv3065 was associated with resistance to the combination of isoniazid and ethambutol, and these drugs, along with streptomycin, were identified to group together, where efflux-mediated drug resistance appears to be important in M. tuberculosis and follows a constant pattern of induction in multidrug-resistant isolates. Isoniazid and ethambutol combination was also found to be affected in 10% (6/60) of the clinical isolates in the presence of carbonyl cyanide m-chloro phenylhydrazone in resazurin microtitre plate assay, supporting the role of efflux pumps in the resistance to these drugs. Overexpression of two of the genes (Rv2477 and Rv2209) has also been observed with ofloxacin stress in M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20001742     DOI: 10.1089/mdr.2009.0054

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  49 in total

1.  Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery.

Authors:  Meenakshi Balganesh; Sanjana Kuruppath; Nimi Marcel; Sreevalli Sharma; Anju Nair; Umender Sharma
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Protein-protein interaction networks suggest different targets have different propensities for triggering drug resistance.

Authors:  Jyothi Padiadpu; Rohit Vashisht; Nagasuma Chandra
Journal:  Syst Synth Biol       Date:  2011-02-20

3.  Antimycobacterial activity of five efflux pump inhibitors against Mycobacterium tuberculosis clinical isolates.

Authors:  Guilian Li; Jingrui Zhang; Chao Li; Qian Guo; Yi Jiang; Jianhao Wei; Yan Qiu; Xiuqin Zhao; Li-li Zhao; Jianxin Lu; Kanglin Wan
Journal:  J Antibiot (Tokyo)       Date:  2015-10-14       Impact factor: 2.649

4.  Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling.

Authors:  Griselda Tudó; Ken Laing; Denis A Mitchison; Philip D Butcher; Simon J Waddell
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

5.  Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates.

Authors:  Meenakshi Balganesh; Neela Dinesh; Sreevalli Sharma; Sanjana Kuruppath; Anju V Nair; Umender Sharma
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

6.  Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.

Authors:  Shashank Gupta; Sandeep Tyagi; Deepak V Almeida; Mariama C Maiga; Nicole C Ammerman; William R Bishai
Journal:  Am J Respir Crit Care Med       Date:  2013-09-01       Impact factor: 21.405

7.  Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations.

Authors:  John D Szumowski; Kristin N Adams; Paul H Edelstein; Lalita Ramakrishnan
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 8.  Mycobacterium tuberculosis Major Facilitator Superfamily Transporters.

Authors:  Ping Li; Yinzhong Gu; Jiang Li; Longxiang Xie; Xue Li; Jianping Xie
Journal:  J Membr Biol       Date:  2017-08-29       Impact factor: 1.843

9.  Involvement of efflux pumps in the resistance to peptidoglycan synthesis inhibitors in Mycobacterium tuberculosis.

Authors:  Neela Dinesh; Sreevalli Sharma; Meenakshi Balganesh
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

10.  Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis.

Authors:  Jansy Sarathy; Véronique Dartois; Thomas Dick; Martin Gengenbacher
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.